Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 16/20 | 0.38 |
| ▸ | CTSK | P43235 | 15/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207826 | 0.82 | MEN1 (0.37) | MCL1 | |
| SCHEMBL6081290 | 0.79 | MCL1 (0.34) | MCL1 | |
| SCHEMBL6081252 | 0.79 | MCL1 (0.34) | MCL1 | |
| SCHEMBL13239370 | 0.74 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL6081292 | 0.72 | MCL1 (0.36) | MCL1 | |
| SCHEMBL2975034 | 0.72 | CTSK (0.33) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6939950 | 0.69 | IDO1 (0.47) | — | |
| SCHEMBL2389781 | 0.68 | CA1 (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL3008867 | 0.68 | CA1 (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL27911439 | 0.68 | MEN1 (0.34) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | CTSS 1869/4885CTSK 530/4885CTSL 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.